Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-930-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$635.98 million
Profitability
Miscellaneous
Employees1,500
OptionableOptionable
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) issued its earnings results on Wednesday, May, 2nd. The medical device company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.36 by $0.05. The medical device company earned $174.41 million during the quarter, compared to analyst estimates of $167.95 million. Globus Medical had a return on equity of 15.36% and a net margin of 20.79%. Globus Medical's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
How can I listen to Globus Medical's earnings call?
Globus Medical will be holding an earnings conference call on Friday, February 22nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8555337141.
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY19 earnings guidance on Tuesday, January, 8th. The company provided earnings per share (EPS) guidance of $1.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.73. The company issued revenue guidance of 770 million, compared to the consensus revenue estimate of $764.15 million.
What price target have analysts set for GMED?
11 analysts have issued twelve-month price objectives for Globus Medical's shares. Their predictions range from $37.00 to $65.00. On average, they anticipate Globus Medical's stock price to reach $55.9091 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $65. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (1/9/2019)
- 2. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (1/8/2019)
Has Globus Medical been receiving favorable news coverage?
Press coverage about GMED stock has been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Globus Medical earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA) and Tandem Diabetes Care (TNDM).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
- Mr. David M. Demski, CEO & Director (Age 61)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
- Mr. David D. Davidar, Co-Founder & Director (Age 53)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.66%), Investec Asset Management LTD (1.52%), Bank of New York Mellon Corp (1.50%), Oregon Public Employees Retirement Fund (1.27%), Victory Capital Management Inc. (1.24%) and Northern Trust Corp (1.21%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which major investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Standard Life Aberdeen plc, Canada Pension Plan Investment Board, Bank of New York Mellon Corp, Gotham Asset Management LLC, Oak Ridge Investments LLC, GW&K Investment Management LLC and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, Daniel T Scavilla, David C Paul, David M Demski, Eric Schwartz and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which major investors are buying Globus Medical stock?
GMED stock was purchased by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Oregon Public Employees Retirement Fund, Legal & General Group Plc, Retirement Systems of Alabama, Squarepoint Ops LLC, Rhumbline Advisers, Kayne Anderson Rudnick Investment Management LLC and Navellier & Associates Inc. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $47.85.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.71 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.
What is Globus Medical's official website?
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
